Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmuronASX:IMC +13.51% Days Sales Outstanding is 38.78 as of Dec. 2025, which is 31% below its 10-year median of 55.99. The stock has 4 warning signs investors should review. Among 836 Biotechnology companies, Immuron ranks better than 67.58% on this metric.
Immuron's average Accounts Receivable for the
six
months ended in Dec. 2025 was A$0.89 Mil. Immuron's Revenue for the
six
months ended in Dec. 2025 was A$4.18 Mil.
Hence, Immuron's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 38.78.
The historical rank and industry rank for Immuron's Days Sales Outstanding or its related term are showing as below:
ASX:IMC'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 22.71 Med: 55.99 Max: 75.46
Current: 47.61
During the past 12 years, Immuron's highest Days Sales Outstanding was 75.46. The lowest was 22.71. And the median was 55.99.
ASX:IMC's Days Sales Outstanding is ranked better than 67.58% of 836
companies
in the Biotechnology industry
Industry Median: 68.79
vs ASX:IMC: 47.61
Immuron's Days Sales Outstanding
declined
from Dec. 2024 (39.73) to Dec. 2025 (38.78).
Immuron (ASX:IMC) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Immuron Days Sales Outstanding Related Terms
Immuron Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Immuron's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IMC vs VRTX, REGN, RVMD: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Immuron's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immuron Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immuron's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Immuron's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immuron (ASX:IMC) has a Days Sales Outstanding of 38.78 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Immuron and its competitors. This is 31% below median its historical median of 55.99. Over the past decade, Immuron's Days Sales Outstanding has ranged from 22.71 to 75.46. According to the industry distribution chart, Immuron ranks #271 out of 836 companies in the Biotechnology industry, placing it in the top 32.4%.
Is Immuron's Days Sales Outstanding too high?
Immuron's current Days Sales Outstanding of 38.78 is 31% below median its 10-year median of 55.99. Over the past 10 years, this metric has ranged from a low of 22.71 to a high of 75.46. The Biotechnology industry median Days Sales Outstanding is 68.79. Immuron's value of 38.78 is 43.6% below this industry median. Based on the distribution chart, Immuron ranks #271 out of 836 companies in the Biotechnology industry, which is above the industry midpoint.
How does Immuron's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immuron ranks #271 out of 836 companies for Days Sales Outstanding. This puts Immuron in the upper half of its industry. The industry median Days Sales Outstanding is 68.79. Immuron's value of 38.78 is 43.6% below this benchmark. Historically, Immuron's own Days Sales Outstanding has ranged from 22.71 to 75.46 over the past decade. While the company's 10-year median is 55.99 vs. the industry median of 68.79, Immuron has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.79, based on 836 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immuron's current Days Sales Outstanding of 38.78 is 43.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Immuron and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immuron's current Days Sales Outstanding is 38.78, which is 31% below median its own 10-year median of 55.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuron stock overvalued right now?
Immuron (ASX:IMC) has a current Days Sales Outstanding of 38.78. The current Days Sales Outstanding is 38.78, which is 31% below median its 10-year median of 55.99 and 43.6% below the Biotechnology industry median of 68.79. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Immuron (ASX:IMC), the current Days Sales Outstanding is 38.78 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IMC has been successfully added to your 
